Allocated to ASAQ
N=498
Exposed to treatment
N=498 (100%)

Allocated to AL
N=502
Exposed to treatment
N=502 (100%)

Screening failures N=250 (20%)
205 No microscopic confirmation of asexual Pf or mixed infection
26 No willingness to attend follow up
26 Informed consent not signed
10 Pregnancy
8 Severe anemia (<5 g/dl Hemoglobin)
5 Age ≤ 5 years
5 Concomitant febrile illness and medication required
3 anti-malarial treatment in previous 4 weeks

Assessed for eligibility N=1254∗
N=2 excluded from analysis (second participation)

Analysed (safety population) N=496 (99.6%)
Completed 28 days follow up N=466 (93.6 %)
Premature discontinuation:
Lost to follow up 7 (1.4 %)
Withdrawal of consent 1 (0.2 %)
Unable to attend follow up visit on time 14 (2.8 %)
Recurrence of Parasitaemia 3 (0.6 %)
Incorrect enrolment ± 3 (0.6 %)
Incorrect withdrawal ± ± 1 (0.2 %)
Withdrawn for safety reasons ψ 1 (0.2 %)

Analysed (safety population) N=502 (100%)
Completed 28 days follow up N=478 (95.2%)
Premature discontinuation:
Lost to follow up 5 (1.0 %)
Withdrawal of consent 2 (0.4 %)
Unable to attend follow up visit on time 15 (2.9 %)
Recurrence of Parasitaemia 1 (0.2 %)
Incorrect enrolment ± 1 (0.2 %)
Incorrect withdrawal -
Withdrawn for safety reason -

Screening failures N=250 (20%)
205 No microscopic confirmation of asexual Pf or mixed infection
26 No willingness to attend follow up
26 Informed consent not signed
10 Pregnancy
8 Severe anemia (<5 g/dl Hemoglobin)
5 Age ≤ 5 years
5 Concomitant febrile illness and medication required
3 anti-malarial treatment in previous 4 weeks

Randomized N=1000

Analysed (safety population) N=1000